VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
ASCO 2026: Lorlatinib Shows Unprecedented 7-Year Results — 55% of Advanced NSCLC Patients Remain Progression-Free, Median PFS Expected to Reach 10 Years
ASCO 2026: Lorlatinib Shows Unprecedented 7-Year Results — 55% of Advanced NSCLC Patients Remain Progression-Free, Median PFS Expected to Reach 10 Years
May 30, 2026 13:32 CST Updated 15:46
Share: